Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Steward Hospital Sales topic
No spam. Unsubscribe anytime.
HPC says Steward hospital sales preserve access; declines to open cost-and-market reviews
Summary
After rapid, in‑depth review of five Steward hospital sales completed Sept. 30, the Health Policy Commission concluded the acquisitions are unlikely to raise statewide spending and chose not to proceed to formal cost-and-market-impact reviews, while pledging ongoing monitoring and pointing to DO program conditions and operator commitments to preserve services.
The Massachusetts Health Policy Commission reported on its public review of five Steward Healthcare hospital sales and concluded its findings did not show evidence the transactions would materially increase health‑care spending or impair market functioning. The presentation, delivered by Megan Wolf on behalf of HPC staff, covered acquisitions completed on Sept. 30 and hospital transfers that went into effect Oct. 1.
The HPC noted the transactions — including Lifespan’s purchase of St. ANS (Fall River) and Morton (Taunton), Lawrence General’s acquisition of the two Holy Family campuses, and Boston Medical Center’s purchase of St. Elizabeth’s and Good Samaritan — represented significant changes but were accompanied by commitments and Determination of Need (DO) program conditions intended to preserve access and limit service disruption. Wolf said Lifespan’s purchase price was cited as $175 million and that Lifespan made commitments tied to supplemental funding to operate Morton as an acute care hospital at least through fiscal year 2027. She told commissioners the DO conditions require good‑faith efforts to participate in the same insurance plans post‑closing and that providers at the hospitals participate in MassHealth within two years.
“The HPC’s review did not uncover evidence that these transactions are likely to significantly increase healthcare spending or negatively impact market functioning,” Wolf said, summarizing the staff conclusion that, in aggregate, statewide market concentration was not expected to rise and some referrals could shift to lower‑priced facilities, potentially reducing spending for Massachusetts patients.
Commissioners pressed staff on the duration and enforceability of commitments. A commissioner asked whether Lifespan’s Morton commitment applied to St. ANS and what constraints would exist after 2027; staff replied that supplemental funding covered Morton but not St. ANS, and the HPC will continue to monitor service lines and filings (for example, essential‑services or DO filings) if operators seek to reduce services beyond their funding commitments.
The commission repeatedly emphasized access to Behavioral Health, labor-and-delivery and emergency services in affected communities. Staff pointed to DO program conditions that include facility improvement and service‑access requirements and said HPC will review materials submitted to the DO program and monitor cost, quality and access metrics for the acquiring parties.
The body voted to close its review and not to proceed to formal cost‑and‑market impact reviews for these hospital transactions, citing the mitigating factors and operator commitments presented in the public filings and DO determinations. HPC staff said they will publish the detailed findings and continue active monitoring of outcomes, including service‑line changes and MassHealth participation.
The meeting exchange underscored commissioners’ concerns about the durability of time‑limited funding commitments, and multiple members urged continued vigilance and stronger statutory tools to hold future buyers to public commitments. The HPC framed the decision not to open further review as conditional: staff will watch for material changes, essential‑services filings, or other notices that could trigger additional oversight.
